Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry

PHASE3CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Asthma
Interventions
DRUG

GW685698/GW642444

ICS/LABA

DRUG

CCI18781

ICS

Trial Locations (24)

1100

GSK Investigational Site, Quezon City

4217

GSK Investigational Site, Lipa City

100020

GSK Investigational Site, Beijing

100029

GSK Investigational Site, Beijing

100191

GSK Investigational Site, Beijing

110001

GSK Investigational Site, Shenyang

110015

GSK Investigational Site, Shenyang

200025

GSK Investigational Site, Shanghai

200032

GSK Investigational Site, Shanghai

200080

GSK Investigational Site, Shanghai

400037

GSK Investigational Site, Chongqing

400038

GSK Investigational Site, Chongqing

410011

GSK Investigational Site, Changsha

411706

GSK Investigational Site, Ilsanseo-gu, Goyang-si, Gyeonggi-do

510120

GSK Investigational Site, Guangzhou

420-767

GSK Investigational Site, Bucheon-si, Gyeonggi-Do

361-711

GSK Investigational Site, Cheongju, Chungcheongbuk-do

602-739

GSK Investigational Site, Pusan

463-707

GSK Investigational Site, Seongnam-si, Gyeonggi-do

110-744

GSK Investigational Site, Seoul

120-752

GSK Investigational Site, Seoul

130-709

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

152-703

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY